Zenas BioPharma, Inc. (ZBIO) Stock Grade

About Zenas BioPharma, Inc.'s fundamentals

Zenas BioPharma is a small-cap biotech company with a $1.6 billion market capitalization that demonstrated strong revenue momentum, growing sales 100% year-over-year. However, the company is unprofitable, reporting a substantial net loss in its latest annual statement with a net margin of -3777.4%, indicating losses far exceed revenue. The company does not pay a dividend and traditional valuation metrics like P/E ratio and return on equity are not applicable due to its loss-making status. This profile is typical of early-stage biotech firms investing heavily in research and development before achieving profitability.